Ozmosi | Cefixime Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Cefixime

Alternative Names: cefixime, suprax, cefixima, cefixim
Clinical Status: Inactive
Latest Update: 2026-01-15
Latest Update Note: Clinical Trial Update

Product Description

Cefixime is used to treat bacterial infections in many different parts of the body. It belongs to the class of medicines known as cephalosporin antibiotics. It works by killing bacteria or preventing their growth. However, this medicine will not work for colds, flu, or other virus infections (Sourced from: https://www.mayoclinic.org/drugs-supplements/cefixime-oral-route/side-effects/drg-20073374?p=1)

Mechanisms of Action: Cell Wall Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Austria | Bangladesh | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Dominican Republic | Ecuador | Egypt | France | Germany | Greece | Hungary | India | Indonesia | Ireland | Italy | Jordan | Korea | Lebanon | Malaysia | Malta | Mexico | Morocco | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated